Claims

1. Use of a morphic form of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Form I), characterized by an X-ray powder diffraction pattern including peaks at about 10.5, 18.7, 22.9, 23.6, and 24.7 degrees 2θ, in the manufacture of a medicament for the treatment of nonalcoholic steatohepatitis in a subject in need thereof.

2. The use of claim 1, wherein the X-ray powder diffraction pattern further includes peaks at about 8.2, 11.2, 15.7, 16.4, 17.7, 30.0, and 32.2 degrees 2θ.

3. The use of claim 1, wherein the morphic form is characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1.

4. The use of claim 1, wherein the morphic form has a purity of Compound A of 95% or greater.

5. Use of a morphic form of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Form I), characterized by an X-ray powder diffraction pattern including peaks at about 10.5, 18.7, 22.9, 23.6, and 24.7 degrees 2θ, in the manufacture of a medicament for the treatment of hypercholesterolemia in a subject in need thereof.

6. The use of claim 5, wherein the X-ray powder diffraction pattern further includes peaks at about 8.2, 11.2, 15.7, 16.4, 17.7, 30.0, and 32.2 degrees 2θ.

7. The use of claim 5, wherein the morphic form is characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1.

8. The use of claim 5, wherein the morphic form has a purity of Compound A of 95% or greater.

9. Use of a morphic form of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Form I), characterized by an X-ray powder diffraction pattern including peaks at about 10.5, 18.7, 22.9, 23.6, and 24.7 degrees 2θ, in the manufacture of a medicament for the treatment of fatty liver disease in a subject in need thereof.

10. The use of claim 9, wherein the X-ray powder diffraction pattern further includes peaks at about 8.2, 11.2, 15.7, 16.4, 17.7, 30.0, and 32.2 degrees 2θ.

11. The use of claim 9, wherein the morphic form is characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1.

12. The use of claim 9, wherein the morphic form has a purity of Compound A of 95% or greater.